Skip to main content

Table 2 Frequency of antimicrobial use among CCRT patients by group

From: Appropriateness of antimicrobial use among septic patients managed by the critical care response team: an opportunity for improvement through de-escalation

 Cases
N = 157
Control
N = 158
Total
N = 315
p-value
Overall antimicrobial use
 At any point157 (100.0%)138 (87.3%)295 (93.7%)< 0.001
 Before CCRT activation129 (82.2%)111 (70.3%)240 (76.2%)0.013
 During CCRT activation151 (96.2%)103 (65.2%)254 (80.6%)< 0.001
 After CCRT activation129 (82.2%)107 (67.7%)236 (74.9%)0.003
Individual antimicrobial use at any point
 Meropenem107 (68.2%)55 (34.8%)162 (51.4%)< 0.001
 Vancomycin89 (56.7%)41 (25.9%)130 (41.3%)< 0.001
 Piperacillin-tazobactam44 (28.0%)46 (29.1%)90 (28.6%)0.831
 Ceftriaxone16 (10.2%)22 (13.9%)38 (12.1%)0.311
 Linezolid21 (13.4%)6 (3.8%)27 (8.6%)0.002
 Colistin13 (8.3%)10 (6.3%)23 (7.3%)0.506
 Caspofungin18 (11.5%)3 (1.9%)21 (6.7%)0.001
 Anidulafungin14 (8.9%)4 (2.5%)18 (5.7%)0.015
 Tigecycline12 (7.6%)5 (3.2%)17 (5.4%)0.079
 Ciprofloxacin6 (3.8%)11 (7.0%)17 (5.4%)0.218
 Imipenem8 (5.1%)6 (3.8%)14 (4.4%)0.576
 Others137 (87.3%)85 (53.8%)222 (70.5%)< 0.001
Antimicrobial change after CCRT activation
 New prescription254 (45.4%)117 (36.6%)371 (42.2%)0.010
 Continuation305 (54.6%)203 (63.4%)508 (57.8%)